Markets:

Overview

News

Currencies

International

Treasuries

Articles published by EnPlusOne Biosciences, Inc.

Nitto Denko Avecia to Evaluate EnPlusOne’s ezRNA™ Platform for RNA Therapeutics Manufacturing

November 05, 2026

From EnPlusOne Biosciences, Inc.

Via Business Wire

EnPlusOne Biosciences Welcomes Biotech Veteran, Jim Weissman, to Board of Directors

May 28, 2026

From EnPlusOne Biosciences, Inc.

Via Business Wire

EnPlusOne Biosciences Highlights Significant Advancements to its ezRNA™ Enzymatic RNA Synthesis Platform and Introduces Novel Modifications for Next-Generation RNA Therapeutics

May 12, 2026

From EnPlusOne Biosciences, Inc.

Via Business Wire

EnPlusOne Biosciences To Present New Data at TIDES USA

May 15, 2025

From EnPlusOne Biosciences, Inc.

Via Business Wire

EnPlusOne Biosciences Appoints Clare Murray, Ph.D. as CEO

April 17, 2025

From EnPlusOne Biosciences, Inc.

Via Business Wire

EnPlusOne Biosciences Reveals Breakthrough Enzymatic Synthesis of Leqvio® Antisense Strand

July 09, 2024

From EnPlusOne Biosciences, Inc.

Via Business Wire

EnPlusOne Biosciences to Unveil Advances in Enzymatic Synthesis of RNA at TIDES 2024, Leading Conference on Oligonucleotides and Peptide Therapeutics

May 14, 2024

From EnPlusOne Biosciences, Inc.

Via Business Wire

EnPlusOne Biosciences to Address Advances in the Enzymatic Synthesis of RNA at the 11th Annual Oligo Networking Conference

March 04, 2024

From EnPlusOne Biosciences, Inc.

Via Business Wire

EnPlusOne Biosciences to Attend and Present Poster at OTS Annual Meeting

October 20, 2023

From EnPlusOne Biosciences, Inc.

Via Business Wire

EnPlusOne Biosciences Expands Scientific Advisory Board

February 08, 2023

From EnPlusOne Biosciences, Inc.

Via Business Wire

EnPlusOne Biosciences Launches Enzymatic RNA Synthesis Platform with $12 Million in Seed Financing

September 30, 2022

From EnPlusOne Biosciences, Inc.

Via Business Wire

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.